nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—melanoma	0.591	1	CbGaD
Terazosin—Neck pain—Carmustine—melanoma	0.00249	0.00942	CcSEcCtD
Terazosin—Coordination abnormal—Temozolomide—melanoma	0.00243	0.00916	CcSEcCtD
Terazosin—Musculoskeletal pain—Temozolomide—melanoma	0.00241	0.00911	CcSEcCtD
Terazosin—Urinary incontinence—Carmustine—melanoma	0.00238	0.00899	CcSEcCtD
Terazosin—Oedema peripheral—Vemurafenib—melanoma	0.00231	0.00871	CcSEcCtD
Terazosin—Urinary incontinence—Temozolomide—melanoma	0.0023	0.00869	CcSEcCtD
Terazosin—Eye disorder—Vemurafenib—melanoma	0.00219	0.00826	CcSEcCtD
Terazosin—Abnormal vision—Carmustine—melanoma	0.00215	0.00812	CcSEcCtD
Terazosin—Arthritis—Bleomycin—melanoma	0.00211	0.00797	CcSEcCtD
Terazosin—Cerebrovascular accident—Bleomycin—melanoma	0.00209	0.0079	CcSEcCtD
Terazosin—Abnormal vision—Temozolomide—melanoma	0.00208	0.00785	CcSEcCtD
Terazosin—Malnutrition—Vemurafenib—melanoma	0.00204	0.00769	CcSEcCtD
Terazosin—Dysgeusia—Vemurafenib—melanoma	0.002	0.00754	CcSEcCtD
Terazosin—Back pain—Vemurafenib—melanoma	0.00197	0.00744	CcSEcCtD
Terazosin—Nasal congestion—Temozolomide—melanoma	0.0019	0.00717	CcSEcCtD
Terazosin—Cough—Vemurafenib—melanoma	0.00178	0.00671	CcSEcCtD
Terazosin—Myalgia—Vemurafenib—melanoma	0.00173	0.00655	CcSEcCtD
Terazosin—Arthralgia—Vemurafenib—melanoma	0.00173	0.00655	CcSEcCtD
Terazosin—Face oedema—Carmustine—melanoma	0.00173	0.00652	CcSEcCtD
Terazosin—Face oedema—Temozolomide—melanoma	0.00167	0.0063	CcSEcCtD
Terazosin—Anaphylactic shock—Vemurafenib—melanoma	0.00166	0.00628	CcSEcCtD
Terazosin—Hypokalaemia—Carmustine—melanoma	0.00163	0.00615	CcSEcCtD
Terazosin—Hypokalaemia—Temozolomide—melanoma	0.00157	0.00594	CcSEcCtD
Terazosin—Hypotension—Vemurafenib—melanoma	0.00155	0.00587	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00152	0.00572	CcSEcCtD
Terazosin—Decreased appetite—Vemurafenib—melanoma	0.00145	0.00546	CcSEcCtD
Terazosin—Bronchitis—Temozolomide—melanoma	0.00144	0.00543	CcSEcCtD
Terazosin—Fatigue—Vemurafenib—melanoma	0.00143	0.00541	CcSEcCtD
Terazosin—Constipation—Vemurafenib—melanoma	0.00142	0.00537	CcSEcCtD
Terazosin—Dysuria—Temozolomide—melanoma	0.0014	0.00528	CcSEcCtD
Terazosin—Pollakiuria—Temozolomide—melanoma	0.00138	0.00521	CcSEcCtD
Terazosin—Erectile dysfunction—Temozolomide—melanoma	0.00138	0.0052	CcSEcCtD
Terazosin—Depression—Carmustine—melanoma	0.00137	0.00519	CcSEcCtD
Terazosin—Photosensitivity reaction—Temozolomide—melanoma	0.00136	0.00515	CcSEcCtD
Terazosin—Weight increased—Temozolomide—melanoma	0.00136	0.00514	CcSEcCtD
Terazosin—Urinary tract infection—Carmustine—melanoma	0.00134	0.00506	CcSEcCtD
Terazosin—Depression—Temozolomide—melanoma	0.00133	0.00502	CcSEcCtD
Terazosin—Body temperature increased—Vemurafenib—melanoma	0.00131	0.00496	CcSEcCtD
Terazosin—Pharyngitis—Dactinomycin—melanoma	0.00131	0.00496	CcSEcCtD
Terazosin—Urinary tract infection—Temozolomide—melanoma	0.0013	0.00489	CcSEcCtD
Terazosin—Sinusitis—Temozolomide—melanoma	0.00125	0.00472	CcSEcCtD
Terazosin—Hypersensitivity—Vemurafenib—melanoma	0.00123	0.00463	CcSEcCtD
Terazosin—Oedema peripheral—Carmustine—melanoma	0.00122	0.00461	CcSEcCtD
Terazosin—Atrial fibrillation—Docetaxel—melanoma	0.00121	0.00458	CcSEcCtD
Terazosin—Asthenia—Vemurafenib—melanoma	0.00119	0.00451	CcSEcCtD
Terazosin—Visual impairment—Carmustine—melanoma	0.00119	0.0045	CcSEcCtD
Terazosin—Pharyngitis—Temozolomide—melanoma	0.00119	0.00448	CcSEcCtD
Terazosin—Oedema peripheral—Temozolomide—melanoma	0.00118	0.00445	CcSEcCtD
Terazosin—Cardiac failure—Docetaxel—melanoma	0.00118	0.00445	CcSEcCtD
Terazosin—Pruritus—Vemurafenib—melanoma	0.00118	0.00444	CcSEcCtD
Terazosin—Eye disorder—Carmustine—melanoma	0.00116	0.00437	CcSEcCtD
Terazosin—Visual impairment—Temozolomide—melanoma	0.00115	0.00435	CcSEcCtD
Terazosin—Pain in extremity—Docetaxel—melanoma	0.00115	0.00434	CcSEcCtD
Terazosin—Ill-defined disorder—Bleomycin—melanoma	0.00115	0.00433	CcSEcCtD
Terazosin—Diarrhoea—Vemurafenib—melanoma	0.00114	0.0043	CcSEcCtD
Terazosin—Migraine—Docetaxel—melanoma	0.00113	0.00427	CcSEcCtD
Terazosin—Eye disorder—Temozolomide—melanoma	0.00112	0.00422	CcSEcCtD
Terazosin—Tinnitus—Temozolomide—melanoma	0.00112	0.00421	CcSEcCtD
Terazosin—Malaise—Bleomycin—melanoma	0.00111	0.0042	CcSEcCtD
Terazosin—Arrhythmia—Carmustine—melanoma	0.00111	0.00418	CcSEcCtD
Terazosin—Dizziness—Vemurafenib—melanoma	0.0011	0.00415	CcSEcCtD
Terazosin—Malnutrition—Carmustine—melanoma	0.00108	0.00407	CcSEcCtD
Terazosin—Cough—Bleomycin—melanoma	0.00108	0.00407	CcSEcCtD
Terazosin—Ill-defined disorder—Dactinomycin—melanoma	0.00107	0.00403	CcSEcCtD
Terazosin—Vomiting—Vemurafenib—melanoma	0.00106	0.00399	CcSEcCtD
Terazosin—Myalgia—Bleomycin—melanoma	0.00105	0.00397	CcSEcCtD
Terazosin—Chest pain—Bleomycin—melanoma	0.00105	0.00397	CcSEcCtD
Terazosin—Orthostatic hypotension—Docetaxel—melanoma	0.00105	0.00397	CcSEcCtD
Terazosin—Rash—Vemurafenib—melanoma	0.00105	0.00396	CcSEcCtD
Terazosin—Dermatitis—Vemurafenib—melanoma	0.00105	0.00396	CcSEcCtD
Terazosin—Back pain—Carmustine—melanoma	0.00104	0.00394	CcSEcCtD
Terazosin—Headache—Vemurafenib—melanoma	0.00104	0.00393	CcSEcCtD
Terazosin—Malnutrition—Temozolomide—melanoma	0.00104	0.00393	CcSEcCtD
Terazosin—Discomfort—Bleomycin—melanoma	0.00104	0.00392	CcSEcCtD
Terazosin—Malaise—Dactinomycin—melanoma	0.00104	0.00392	CcSEcCtD
Terazosin—Nasopharyngitis—Docetaxel—melanoma	0.00103	0.00388	CcSEcCtD
Terazosin—Dysgeusia—Temozolomide—melanoma	0.00102	0.00385	CcSEcCtD
Terazosin—Confusional state—Bleomycin—melanoma	0.00102	0.00384	CcSEcCtD
Terazosin—Vision blurred—Carmustine—melanoma	0.00102	0.00384	CcSEcCtD
Terazosin—Tremor—Carmustine—melanoma	0.00101	0.00381	CcSEcCtD
Terazosin—Oedema—Bleomycin—melanoma	0.00101	0.0038	CcSEcCtD
Terazosin—Anaphylactic shock—Bleomycin—melanoma	0.00101	0.0038	CcSEcCtD
Terazosin—Back pain—Temozolomide—melanoma	0.00101	0.0038	CcSEcCtD
Terazosin—Nausea—Vemurafenib—melanoma	0.000988	0.00373	CcSEcCtD
Terazosin—Thrombocytopenia—Bleomycin—melanoma	0.000986	0.00373	CcSEcCtD
Terazosin—Vision blurred—Temozolomide—melanoma	0.000981	0.00371	CcSEcCtD
Terazosin—Myalgia—Dactinomycin—melanoma	0.00098	0.0037	CcSEcCtD
Terazosin—Tremor—Temozolomide—melanoma	0.000976	0.00368	CcSEcCtD
Terazosin—Discomfort—Dactinomycin—melanoma	0.000968	0.00366	CcSEcCtD
Terazosin—Angina pectoris—Docetaxel—melanoma	0.000968	0.00366	CcSEcCtD
Terazosin—Ill-defined disorder—Temozolomide—melanoma	0.000966	0.00365	CcSEcCtD
Terazosin—Anorexia—Bleomycin—melanoma	0.00096	0.00363	CcSEcCtD
Terazosin—Angioedema—Temozolomide—melanoma	0.000952	0.00359	CcSEcCtD
Terazosin—Hypotension—Bleomycin—melanoma	0.000941	0.00356	CcSEcCtD
Terazosin—Oedema—Dactinomycin—melanoma	0.00094	0.00355	CcSEcCtD
Terazosin—Malaise—Temozolomide—melanoma	0.000939	0.00355	CcSEcCtD
Terazosin—Vertigo—Temozolomide—melanoma	0.000936	0.00353	CcSEcCtD
Terazosin—Convulsion—Carmustine—melanoma	0.000934	0.00353	CcSEcCtD
Terazosin—Palpitations—Temozolomide—melanoma	0.00092	0.00348	CcSEcCtD
Terazosin—Thrombocytopenia—Dactinomycin—melanoma	0.00092	0.00347	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Bleomycin—melanoma	0.000918	0.00347	CcSEcCtD
Terazosin—Chest pain—Carmustine—melanoma	0.000917	0.00346	CcSEcCtD
Terazosin—Myalgia—Carmustine—melanoma	0.000917	0.00346	CcSEcCtD
Terazosin—Anxiety—Carmustine—melanoma	0.000914	0.00345	CcSEcCtD
Terazosin—Cough—Temozolomide—melanoma	0.000909	0.00343	CcSEcCtD
Terazosin—Paraesthesia—Bleomycin—melanoma	0.000905	0.00342	CcSEcCtD
Terazosin—Weight increased—Docetaxel—melanoma	0.000905	0.00342	CcSEcCtD
Terazosin—Convulsion—Temozolomide—melanoma	0.000902	0.00341	CcSEcCtD
Terazosin—Dyspnoea—Bleomycin—melanoma	0.000898	0.00339	CcSEcCtD
Terazosin—Anorexia—Dactinomycin—melanoma	0.000896	0.00338	CcSEcCtD
Terazosin—Confusional state—Carmustine—melanoma	0.000887	0.00335	CcSEcCtD
Terazosin—Arthralgia—Temozolomide—melanoma	0.000887	0.00335	CcSEcCtD
Terazosin—Myalgia—Temozolomide—melanoma	0.000887	0.00335	CcSEcCtD
Terazosin—Anxiety—Temozolomide—melanoma	0.000884	0.00334	CcSEcCtD
Terazosin—Oedema—Carmustine—melanoma	0.000879	0.00332	CcSEcCtD
Terazosin—Discomfort—Temozolomide—melanoma	0.000876	0.00331	CcSEcCtD
Terazosin—Decreased appetite—Bleomycin—melanoma	0.000876	0.00331	CcSEcCtD
Terazosin—Dry mouth—Temozolomide—melanoma	0.000867	0.00327	CcSEcCtD
Terazosin—Jaundice—Docetaxel—melanoma	0.000864	0.00326	CcSEcCtD
Terazosin—Pain—Bleomycin—melanoma	0.000862	0.00325	CcSEcCtD
Terazosin—Conjunctivitis—Docetaxel—melanoma	0.000861	0.00325	CcSEcCtD
Terazosin—Thrombocytopenia—Carmustine—melanoma	0.000861	0.00325	CcSEcCtD
Terazosin—Tachycardia—Carmustine—melanoma	0.000858	0.00324	CcSEcCtD
Terazosin—Confusional state—Temozolomide—melanoma	0.000857	0.00324	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000856	0.00323	CcSEcCtD
Terazosin—Oedema—Temozolomide—melanoma	0.00085	0.00321	CcSEcCtD
Terazosin—Anaphylactic shock—Temozolomide—melanoma	0.00085	0.00321	CcSEcCtD
Terazosin—Anorexia—Carmustine—melanoma	0.000838	0.00317	CcSEcCtD
Terazosin—Epistaxis—Docetaxel—melanoma	0.000836	0.00316	CcSEcCtD
Terazosin—Thrombocytopenia—Temozolomide—melanoma	0.000832	0.00314	CcSEcCtD
Terazosin—Feeling abnormal—Bleomycin—melanoma	0.00083	0.00314	CcSEcCtD
Terazosin—Hypotension—Carmustine—melanoma	0.000822	0.0031	CcSEcCtD
Terazosin—Hyperhidrosis—Temozolomide—melanoma	0.000822	0.0031	CcSEcCtD
Terazosin—Decreased appetite—Dactinomycin—melanoma	0.000817	0.00308	CcSEcCtD
Terazosin—Fatigue—Dactinomycin—melanoma	0.00081	0.00306	CcSEcCtD
Terazosin—Anorexia—Temozolomide—melanoma	0.00081	0.00306	CcSEcCtD
Terazosin—Pain—Dactinomycin—melanoma	0.000804	0.00303	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Carmustine—melanoma	0.000801	0.00303	CcSEcCtD
Terazosin—Rhinitis—Docetaxel—melanoma	0.000798	0.00301	CcSEcCtD
Terazosin—Body temperature increased—Bleomycin—melanoma	0.000796	0.00301	CcSEcCtD
Terazosin—Insomnia—Carmustine—melanoma	0.000795	0.003	CcSEcCtD
Terazosin—Paraesthesia—Carmustine—melanoma	0.00079	0.00298	CcSEcCtD
Terazosin—Pharyngitis—Docetaxel—melanoma	0.00079	0.00298	CcSEcCtD
Terazosin—Dyspnoea—Carmustine—melanoma	0.000784	0.00296	CcSEcCtD
Terazosin—Oedema peripheral—Docetaxel—melanoma	0.000784	0.00296	CcSEcCtD
Terazosin—Somnolence—Carmustine—melanoma	0.000782	0.00295	CcSEcCtD
Terazosin—Feeling abnormal—Dactinomycin—melanoma	0.000774	0.00292	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Temozolomide—melanoma	0.000774	0.00292	CcSEcCtD
Terazosin—Insomnia—Temozolomide—melanoma	0.000769	0.0029	CcSEcCtD
Terazosin—Gastrointestinal pain—Dactinomycin—melanoma	0.000768	0.0029	CcSEcCtD
Terazosin—Visual impairment—Docetaxel—melanoma	0.000767	0.0029	CcSEcCtD
Terazosin—Decreased appetite—Carmustine—melanoma	0.000765	0.00289	CcSEcCtD
Terazosin—Paraesthesia—Temozolomide—melanoma	0.000763	0.00288	CcSEcCtD
Terazosin—Dyspnoea—Temozolomide—melanoma	0.000758	0.00286	CcSEcCtD
Terazosin—Somnolence—Temozolomide—melanoma	0.000756	0.00285	CcSEcCtD
Terazosin—Pain—Carmustine—melanoma	0.000752	0.00284	CcSEcCtD
Terazosin—Constipation—Carmustine—melanoma	0.000752	0.00284	CcSEcCtD
Terazosin—Dyspepsia—Temozolomide—melanoma	0.000748	0.00283	CcSEcCtD
Terazosin—Eye disorder—Docetaxel—melanoma	0.000743	0.00281	CcSEcCtD
Terazosin—Abdominal pain—Dactinomycin—melanoma	0.000743	0.00281	CcSEcCtD
Terazosin—Body temperature increased—Dactinomycin—melanoma	0.000743	0.00281	CcSEcCtD
Terazosin—Hypersensitivity—Bleomycin—melanoma	0.000742	0.0028	CcSEcCtD
Terazosin—Decreased appetite—Temozolomide—melanoma	0.000739	0.00279	CcSEcCtD
Terazosin—Fatigue—Temozolomide—melanoma	0.000733	0.00277	CcSEcCtD
Terazosin—Pain—Temozolomide—melanoma	0.000727	0.00274	CcSEcCtD
Terazosin—Constipation—Temozolomide—melanoma	0.000727	0.00274	CcSEcCtD
Terazosin—Feeling abnormal—Carmustine—melanoma	0.000725	0.00274	CcSEcCtD
Terazosin—Asthenia—Bleomycin—melanoma	0.000723	0.00273	CcSEcCtD
Terazosin—Gastrointestinal pain—Carmustine—melanoma	0.000719	0.00272	CcSEcCtD
Terazosin—Pruritus—Bleomycin—melanoma	0.000713	0.00269	CcSEcCtD
Terazosin—Arrhythmia—Docetaxel—melanoma	0.000711	0.00268	CcSEcCtD
Terazosin—Feeling abnormal—Temozolomide—melanoma	0.0007	0.00264	CcSEcCtD
Terazosin—Body temperature increased—Carmustine—melanoma	0.000695	0.00263	CcSEcCtD
Terazosin—Abdominal pain—Carmustine—melanoma	0.000695	0.00263	CcSEcCtD
Terazosin—Gastrointestinal pain—Temozolomide—melanoma	0.000695	0.00262	CcSEcCtD
Terazosin—Malnutrition—Docetaxel—melanoma	0.000693	0.00262	CcSEcCtD
Terazosin—Hypersensitivity—Dactinomycin—melanoma	0.000692	0.00261	CcSEcCtD
Terazosin—Dysgeusia—Docetaxel—melanoma	0.000678	0.00256	CcSEcCtD
Terazosin—Asthenia—Dactinomycin—melanoma	0.000674	0.00255	CcSEcCtD
Terazosin—Body temperature increased—Temozolomide—melanoma	0.000672	0.00254	CcSEcCtD
Terazosin—Abdominal pain—Temozolomide—melanoma	0.000672	0.00254	CcSEcCtD
Terazosin—Back pain—Docetaxel—melanoma	0.00067	0.00253	CcSEcCtD
Terazosin—Hypersensitivity—Carmustine—melanoma	0.000648	0.00245	CcSEcCtD
Terazosin—Diarrhoea—Dactinomycin—melanoma	0.000643	0.00243	CcSEcCtD
Terazosin—Vomiting—Bleomycin—melanoma	0.000641	0.00242	CcSEcCtD
Terazosin—Rash—Bleomycin—melanoma	0.000635	0.0024	CcSEcCtD
Terazosin—Dermatitis—Bleomycin—melanoma	0.000635	0.0024	CcSEcCtD
Terazosin—Asthenia—Carmustine—melanoma	0.000631	0.00238	CcSEcCtD
Terazosin—Hypersensitivity—Temozolomide—melanoma	0.000626	0.00236	CcSEcCtD
Terazosin—Syncope—Docetaxel—melanoma	0.000621	0.00235	CcSEcCtD
Terazosin—Palpitations—Docetaxel—melanoma	0.000612	0.00231	CcSEcCtD
Terazosin—Asthenia—Temozolomide—melanoma	0.00061	0.0023	CcSEcCtD
Terazosin—Loss of consciousness—Docetaxel—melanoma	0.000609	0.0023	CcSEcCtD
Terazosin—Cough—Docetaxel—melanoma	0.000604	0.00228	CcSEcCtD
Terazosin—Diarrhoea—Carmustine—melanoma	0.000602	0.00227	CcSEcCtD
Terazosin—Pruritus—Temozolomide—melanoma	0.000601	0.00227	CcSEcCtD
Terazosin—Convulsion—Docetaxel—melanoma	0.0006	0.00227	CcSEcCtD
Terazosin—Nausea—Bleomycin—melanoma	0.000598	0.00226	CcSEcCtD
Terazosin—Vomiting—Dactinomycin—melanoma	0.000597	0.00226	CcSEcCtD
Terazosin—Rash—Dactinomycin—melanoma	0.000592	0.00224	CcSEcCtD
Terazosin—Arthralgia—Docetaxel—melanoma	0.00059	0.00223	CcSEcCtD
Terazosin—Chest pain—Docetaxel—melanoma	0.00059	0.00223	CcSEcCtD
Terazosin—Myalgia—Docetaxel—melanoma	0.00059	0.00223	CcSEcCtD
Terazosin—Dizziness—Carmustine—melanoma	0.000582	0.0022	CcSEcCtD
Terazosin—Diarrhoea—Temozolomide—melanoma	0.000582	0.0022	CcSEcCtD
Terazosin—Dry mouth—Docetaxel—melanoma	0.000577	0.00218	CcSEcCtD
Terazosin—Confusional state—Docetaxel—melanoma	0.00057	0.00215	CcSEcCtD
Terazosin—Anaphylactic shock—Docetaxel—melanoma	0.000565	0.00213	CcSEcCtD
Terazosin—Oedema—Docetaxel—melanoma	0.000565	0.00213	CcSEcCtD
Terazosin—Dizziness—Temozolomide—melanoma	0.000562	0.00212	CcSEcCtD
Terazosin—Vomiting—Carmustine—melanoma	0.000559	0.00211	CcSEcCtD
Terazosin—Nausea—Dactinomycin—melanoma	0.000558	0.00211	CcSEcCtD
Terazosin—Shock—Docetaxel—melanoma	0.000556	0.0021	CcSEcCtD
Terazosin—Rash—Carmustine—melanoma	0.000555	0.00209	CcSEcCtD
Terazosin—Dermatitis—Carmustine—melanoma	0.000554	0.00209	CcSEcCtD
Terazosin—Thrombocytopenia—Docetaxel—melanoma	0.000553	0.00209	CcSEcCtD
Terazosin—Tachycardia—Docetaxel—melanoma	0.000552	0.00208	CcSEcCtD
Terazosin—Headache—Carmustine—melanoma	0.000551	0.00208	CcSEcCtD
Terazosin—Vomiting—Temozolomide—melanoma	0.00054	0.00204	CcSEcCtD
Terazosin—Anorexia—Docetaxel—melanoma	0.000539	0.00203	CcSEcCtD
Terazosin—Rash—Temozolomide—melanoma	0.000536	0.00202	CcSEcCtD
Terazosin—Dermatitis—Temozolomide—melanoma	0.000535	0.00202	CcSEcCtD
Terazosin—Headache—Temozolomide—melanoma	0.000532	0.00201	CcSEcCtD
Terazosin—Hypotension—Docetaxel—melanoma	0.000528	0.00199	CcSEcCtD
Terazosin—Nausea—Carmustine—melanoma	0.000522	0.00197	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000515	0.00194	CcSEcCtD
Terazosin—Insomnia—Docetaxel—melanoma	0.000511	0.00193	CcSEcCtD
Terazosin—Paraesthesia—Docetaxel—melanoma	0.000508	0.00192	CcSEcCtD
Terazosin—Nausea—Temozolomide—melanoma	0.000505	0.00191	CcSEcCtD
Terazosin—Dyspnoea—Docetaxel—melanoma	0.000504	0.0019	CcSEcCtD
Terazosin—Somnolence—Docetaxel—melanoma	0.000502	0.0019	CcSEcCtD
Terazosin—Dyspepsia—Docetaxel—melanoma	0.000498	0.00188	CcSEcCtD
Terazosin—Decreased appetite—Docetaxel—melanoma	0.000491	0.00186	CcSEcCtD
Terazosin—Fatigue—Docetaxel—melanoma	0.000487	0.00184	CcSEcCtD
Terazosin—Constipation—Docetaxel—melanoma	0.000483	0.00183	CcSEcCtD
Terazosin—Pain—Docetaxel—melanoma	0.000483	0.00183	CcSEcCtD
Terazosin—Feeling abnormal—Docetaxel—melanoma	0.000466	0.00176	CcSEcCtD
Terazosin—Gastrointestinal pain—Docetaxel—melanoma	0.000462	0.00175	CcSEcCtD
Terazosin—Body temperature increased—Docetaxel—melanoma	0.000447	0.00169	CcSEcCtD
Terazosin—Abdominal pain—Docetaxel—melanoma	0.000447	0.00169	CcSEcCtD
Terazosin—Doxazosin—ABCB1—melanoma	0.000428	0.52	CrCbGaD
Terazosin—Hypersensitivity—Docetaxel—melanoma	0.000416	0.00157	CcSEcCtD
Terazosin—Asthenia—Docetaxel—melanoma	0.000406	0.00153	CcSEcCtD
Terazosin—Pruritus—Docetaxel—melanoma	0.0004	0.00151	CcSEcCtD
Terazosin—Prazosin—ABCB1—melanoma	0.000394	0.48	CrCbGaD
Terazosin—Diarrhoea—Docetaxel—melanoma	0.000387	0.00146	CcSEcCtD
Terazosin—Dizziness—Docetaxel—melanoma	0.000374	0.00141	CcSEcCtD
Terazosin—Vomiting—Docetaxel—melanoma	0.000359	0.00136	CcSEcCtD
Terazosin—Rash—Docetaxel—melanoma	0.000356	0.00135	CcSEcCtD
Terazosin—Dermatitis—Docetaxel—melanoma	0.000356	0.00134	CcSEcCtD
Terazosin—Headache—Docetaxel—melanoma	0.000354	0.00134	CcSEcCtD
Terazosin—Nausea—Docetaxel—melanoma	0.000336	0.00127	CcSEcCtD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CD—melanoma	3.07e-05	0.000215	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT3—melanoma	3.04e-05	0.000213	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ITGAV—melanoma	3.04e-05	0.000213	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NGFR—melanoma	3.04e-05	0.000213	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—VCAN—melanoma	3.03e-05	0.000212	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGF1—melanoma	3.01e-05	0.00021	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CSF2—melanoma	3.01e-05	0.00021	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—IL2—melanoma	2.96e-05	0.000207	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HDAC2—melanoma	2.96e-05	0.000207	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FOXO4—melanoma	2.96e-05	0.000207	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCR4—melanoma	2.96e-05	0.000207	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—E2F1—melanoma	2.94e-05	0.000206	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CB—melanoma	2.93e-05	0.000205	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GNAQ—melanoma	2.93e-05	0.000205	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PDGFRA—melanoma	2.91e-05	0.000204	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ITGB3—melanoma	2.88e-05	0.000202	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PRKCA—melanoma	2.88e-05	0.000202	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SPP1—melanoma	2.83e-05	0.000198	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAP2K2—melanoma	2.82e-05	0.000197	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CG—melanoma	2.82e-05	0.000197	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCL8—melanoma	2.82e-05	0.000197	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SOCS1—melanoma	2.81e-05	0.000197	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAP2K1—melanoma	2.81e-05	0.000196	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—S100B—melanoma	2.81e-05	0.000196	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CD—melanoma	2.79e-05	0.000195	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SYK—melanoma	2.75e-05	0.000192	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CD—melanoma	2.73e-05	0.000191	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ITGAV—melanoma	2.7e-05	0.000189	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NGFR—melanoma	2.7e-05	0.000189	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT3—melanoma	2.7e-05	0.000189	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL2—melanoma	2.69e-05	0.000188	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB4—melanoma	2.69e-05	0.000188	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TERT—melanoma	2.68e-05	0.000188	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CB—melanoma	2.68e-05	0.000187	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAC1—melanoma	2.67e-05	0.000187	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN2B—melanoma	2.66e-05	0.000186	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.63e-05	0.000184	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CD86—melanoma	2.57e-05	0.00018	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCL8—melanoma	2.57e-05	0.00018	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HIF1A—melanoma	2.56e-05	0.000179	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP17A1—melanoma	2.56e-05	0.000179	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EDN1—melanoma	2.55e-05	0.000179	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SOCS1—melanoma	2.5e-05	0.000175	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGF1—melanoma	2.5e-05	0.000175	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CSF2—melanoma	2.5e-05	0.000175	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAP2K1—melanoma	2.49e-05	0.000174	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—S100B—melanoma	2.49e-05	0.000174	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CD—melanoma	2.48e-05	0.000173	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—IL2—melanoma	2.46e-05	0.000172	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KDR—melanoma	2.45e-05	0.000171	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—E2F1—melanoma	2.44e-05	0.000171	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CB—melanoma	2.43e-05	0.00017	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GNA11—melanoma	2.42e-05	0.000169	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDGFRA—melanoma	2.42e-05	0.000169	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ITGB3—melanoma	2.39e-05	0.000167	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PRKCA—melanoma	2.39e-05	0.000167	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB4—melanoma	2.39e-05	0.000167	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CB—melanoma	2.38e-05	0.000166	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.37e-05	0.000166	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—FASN—melanoma	2.37e-05	0.000166	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN2B—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FN1—melanoma	2.36e-05	0.000165	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SPP1—melanoma	2.35e-05	0.000164	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAP2K2—melanoma	2.34e-05	0.000164	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL8—melanoma	2.34e-05	0.000163	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC5A5—melanoma	2.33e-05	0.000163	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH1—melanoma	2.31e-05	0.000162	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CD86—melanoma	2.29e-05	0.00016	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL8—melanoma	2.29e-05	0.00016	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EDN1—melanoma	2.27e-05	0.000159	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CD80—melanoma	2.26e-05	0.000158	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—APC—melanoma	2.26e-05	0.000158	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CG—melanoma	2.26e-05	0.000158	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KIT—melanoma	2.26e-05	0.000158	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—NRAS—melanoma	2.26e-05	0.000158	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CD44—melanoma	2.25e-05	0.000157	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GNAQ—melanoma	2.25e-05	0.000157	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL2—melanoma	2.23e-05	0.000156	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGF—melanoma	2.23e-05	0.000156	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TERT—melanoma	2.22e-05	0.000156	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAC1—melanoma	2.22e-05	0.000155	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF1—melanoma	2.22e-05	0.000155	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CSF2—melanoma	2.22e-05	0.000155	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—IL2—melanoma	2.18e-05	0.000153	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—E2F1—melanoma	2.17e-05	0.000152	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—MAPK3—melanoma	2.16e-05	0.000151	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CB—melanoma	2.16e-05	0.000151	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1B1—melanoma	2.16e-05	0.000151	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFRA—melanoma	2.15e-05	0.00015	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HIF1A—melanoma	2.13e-05	0.000149	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PRKCA—melanoma	2.13e-05	0.000149	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ITGB3—melanoma	2.13e-05	0.000149	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BRAF—melanoma	2.12e-05	0.000148	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SPP1—melanoma	2.08e-05	0.000146	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAP2K2—melanoma	2.08e-05	0.000145	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL8—melanoma	2.08e-05	0.000145	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IGF1—melanoma	2.07e-05	0.000145	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—MAPK1—melanoma	2.06e-05	0.000144	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—melanoma	2.06e-05	0.000144	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KDR—melanoma	2.03e-05	0.000142	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAP2K1—melanoma	2e-05	0.00014	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CD—melanoma	1.99e-05	0.000139	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL2—melanoma	1.98e-05	0.000139	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TERT—melanoma	1.98e-05	0.000138	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAC1—melanoma	1.97e-05	0.000138	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—melanoma	1.97e-05	0.000138	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FN1—melanoma	1.96e-05	0.000137	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—KRAS—melanoma	1.94e-05	0.000136	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH1—melanoma	1.92e-05	0.000134	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGF2—melanoma	1.9e-05	0.000133	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HIF1A—melanoma	1.89e-05	0.000132	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CD80—melanoma	1.88e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—APC—melanoma	1.87e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KIT—melanoma	1.87e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CG—melanoma	1.87e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—NRAS—melanoma	1.87e-05	0.000131	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGF—melanoma	1.85e-05	0.00013	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KDR—melanoma	1.81e-05	0.000126	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAPK3—melanoma	1.8e-05	0.000126	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—melanoma	1.79e-05	0.000125	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MDM2—melanoma	1.78e-05	0.000124	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BRAF—melanoma	1.76e-05	0.000123	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB2—melanoma	1.75e-05	0.000123	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FN1—melanoma	1.74e-05	0.000122	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CB—melanoma	1.73e-05	0.000121	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IGF1—melanoma	1.72e-05	0.00012	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAPK1—melanoma	1.71e-05	0.000119	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—melanoma	1.71e-05	0.000119	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH1—melanoma	1.7e-05	0.000119	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CD80—melanoma	1.67e-05	0.000117	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CG—melanoma	1.67e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KIT—melanoma	1.67e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—APC—melanoma	1.67e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—NRAS—melanoma	1.67e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL8—melanoma	1.66e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAP2K1—melanoma	1.66e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HRAS—melanoma	1.65e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CD—melanoma	1.65e-05	0.000115	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGF—melanoma	1.65e-05	0.000115	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PRKCA—melanoma	1.63e-05	0.000114	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	1.63e-05	0.000114	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1B—melanoma	1.62e-05	0.000114	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ERCC2—melanoma	1.62e-05	0.000113	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—KRAS—melanoma	1.61e-05	0.000113	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKT1—melanoma	1.61e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAPK3—melanoma	1.59e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CASP3—melanoma	1.59e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2—melanoma	1.59e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—melanoma	1.58e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGF2—melanoma	1.58e-05	0.00011	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BRAF—melanoma	1.57e-05	0.000109	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—melanoma	1.55e-05	0.000108	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CTNNB1—melanoma	1.53e-05	0.000107	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF1—melanoma	1.52e-05	0.000107	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAPK1—melanoma	1.52e-05	0.000106	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—melanoma	1.52e-05	0.000106	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MMP9—melanoma	1.5e-05	0.000105	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—melanoma	1.5e-05	0.000105	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PTEN—melanoma	1.5e-05	0.000105	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NFKB1—melanoma	1.49e-05	0.000104	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	1.48e-05	0.000104	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MDM2—melanoma	1.48e-05	0.000103	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAP2K1—melanoma	1.47e-05	0.000103	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CD—melanoma	1.46e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKT1—melanoma	1.46e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB2—melanoma	1.46e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	1.45e-05	0.000101	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CB—melanoma	1.44e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—KRAS—melanoma	1.43e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF2—melanoma	1.4e-05	9.8e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL8—melanoma	1.38e-05	9.65e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HRAS—melanoma	1.37e-05	9.59e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—melanoma	1.35e-05	9.45e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1B—melanoma	1.35e-05	9.43e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STAT3—melanoma	1.34e-05	9.36e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NRAS—melanoma	1.33e-05	9.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKT1—melanoma	1.33e-05	9.33e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CASP3—melanoma	1.32e-05	9.24e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2—melanoma	1.32e-05	9.23e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	1.32e-05	9.21e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—melanoma	1.31e-05	9.18e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MDM2—melanoma	1.31e-05	9.17e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB2—melanoma	1.29e-05	9.04e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—melanoma	1.29e-05	8.99e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CG—melanoma	1.28e-05	8.95e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK3—melanoma	1.28e-05	8.94e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CB—melanoma	1.28e-05	8.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CTNNB1—melanoma	1.27e-05	8.91e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MMP9—melanoma	1.25e-05	8.73e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—melanoma	1.24e-05	8.7e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—melanoma	1.24e-05	8.69e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PTEN—melanoma	1.24e-05	8.68e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NFKB1—melanoma	1.24e-05	8.64e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PPARG—melanoma	1.23e-05	8.64e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL8—melanoma	1.23e-05	8.58e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HRAS—melanoma	1.22e-05	8.52e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK1—melanoma	1.22e-05	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—melanoma	1.22e-05	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKT1—melanoma	1.21e-05	8.47e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1B—melanoma	1.2e-05	8.38e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKT1—melanoma	1.18e-05	8.28e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP3—melanoma	1.17e-05	8.21e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2—melanoma	1.17e-05	8.2e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—melanoma	1.17e-05	8.15e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KRAS—melanoma	1.15e-05	8.03e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—melanoma	1.14e-05	7.99e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CTNNB1—melanoma	1.13e-05	7.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CD—melanoma	1.12e-05	7.87e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—melanoma	1.12e-05	7.84e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALB—melanoma	1.11e-05	7.77e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT3—melanoma	1.11e-05	7.76e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP9—melanoma	1.11e-05	7.76e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NRAS—melanoma	1.11e-05	7.75e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—melanoma	1.1e-05	7.73e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PTEN—melanoma	1.1e-05	7.71e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NFKB1—melanoma	1.1e-05	7.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKT1—melanoma	1.08e-05	7.52e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK3—melanoma	1.06e-05	7.42e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—melanoma	1.05e-05	7.38e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—melanoma	1.03e-05	7.21e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—melanoma	1.02e-05	7.14e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK1—melanoma	1.01e-05	7.06e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—melanoma	1.01e-05	7.06e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—melanoma	9.96e-06	6.97e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT3—melanoma	9.86e-06	6.9e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NRAS—melanoma	9.84e-06	6.88e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CB—melanoma	9.8e-06	6.86e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HRAS—melanoma	9.76e-06	6.83e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTGS2—melanoma	9.71e-06	6.79e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KRAS—melanoma	9.53e-06	6.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK3—melanoma	9.42e-06	6.59e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—melanoma	9.34e-06	6.53e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—melanoma	9.16e-06	6.41e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK1—melanoma	8.96e-06	6.27e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—melanoma	8.96e-06	6.27e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—melanoma	8.76e-06	6.12e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT1—melanoma	8.62e-06	6.03e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTEN—melanoma	8.47e-06	5.93e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—melanoma	8.47e-06	5.93e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KRAS—melanoma	8.47e-06	5.92e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HRAS—melanoma	8.1e-06	5.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—melanoma	7.78e-06	5.44e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—melanoma	7.75e-06	5.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—melanoma	7.52e-06	5.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HRAS—melanoma	7.2e-06	5.03e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT1—melanoma	7.15e-06	5e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—melanoma	6.89e-06	4.82e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT1—melanoma	6.35e-06	4.44e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—melanoma	5.98e-06	4.18e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKT1—melanoma	4.88e-06	3.41e-05	CbGpPWpGaD
